Literature DB >> 1633265

Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor.

J A Lust1, K A Donovan, M P Kline, P R Greipp, R A Kyle, N J Maihle.   

Abstract

Soluble forms of the interleukin (IL)-2, IL-4 and IL-7 receptors which lack the transmembrane domain have been described. IL-6 is a growth factor important in the final differentiation of B-cells into plasma cells and in the pathogenesis of multiple myeloma. To determine whether the receptor for IL-6 may exist as a soluble molecule, RNA was analysed from the transformed B-cell lines U266, CESS and Daudi, from bone marrow from two myeloma patients, and from normal leukocytes. Using polymerase chain reaction, oligonucleotide primers which flank the transmembrane domain were selected to generate a 339 bp fragment. All samples produced equivalent amounts of the expected 339 bp fragment plus a smaller 245 bp fragment except Daudi which exhibited virtual absence of both. Sequence analysis of the smaller fragments from each of the five samples demonstrated the deletion of the entire transmembrane region from codons 356 (G-TG) to 387 (AG-G). The boundaries of this deletion were identical in all cases. Partial sequence analysis of the ligand-binding domain for U266 demonstrated identical sequences for the membrane-bound and soluble forms of the IL-6 receptor cDNAs. In summary, an mRNA which encodes a soluble form of the IL-6 receptor is expressed in both normal and myeloma cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1633265     DOI: 10.1016/1043-4666(92)90043-q

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  94 in total

1.  An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.

Authors:  Owen W Stephens; Qing Zhang; Pingping Qu; Yiming Zhou; Shweta Chavan; Erming Tian; David R Williams; Joshua Epstein; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

2.  IL-6 trans-signaling system in intra-amniotic inflammation, preterm birth, and preterm premature rupture of the membranes.

Authors:  Sarah Y Lee; Irina A Buhimschi; Antonette T Dulay; Unzila A Ali; Guomao Zhao; Sonya S Abdel-Razeq; Mert O Bahtiyar; Stephen F Thung; Edmund F Funai; Catalin S Buhimschi
Journal:  J Immunol       Date:  2011-01-31       Impact factor: 5.422

3.  Interleukin 6 is autoregulated by transcriptional mechanisms in cultures of rat osteoblastic cells.

Authors:  N Franchimont; S Rydziel; E Canalis
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

Review 4.  Regulation of a lymphocyte-endothelial-IL-6 trans-signaling axis by fever-range thermal stress: hot spot of immune surveillance.

Authors:  Trupti D Vardam; Lei Zhou; Michelle M Appenheimer; Qing Chen; Wang-Chao Wang; Heinz Baumann; Sharon S Evans
Journal:  Cytokine       Date:  2007-07       Impact factor: 3.861

Review 5.  Interleukin-6: designing specific therapeutics for a complex cytokine.

Authors:  Christoph Garbers; Sylvia Heink; Thomas Korn; Stefan Rose-John
Journal:  Nat Rev Drug Discov       Date:  2018-05-04       Impact factor: 84.694

6.  Interleukin-6-mediated trans-signaling inhibits transforming growth factor-β signaling in trabecular meshwork cells.

Authors:  Miyuki Inoue-Mochita; Toshihiro Inoue; Sachi Kojima; Akiko Futakuchi; Tomokazu Fujimoto; Saori Sato-Ohira; Utako Tsutsumi; Hidenobu Tanihara
Journal:  J Biol Chem       Date:  2018-05-11       Impact factor: 5.157

7.  Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain.

Authors:  Iain L Campbell; Maria Erta; Sue Ling Lim; Ricardo Frausto; Ulrike May; Stefan Rose-John; Jürgen Scheller; Juan Hidalgo
Journal:  J Neurosci       Date:  2014-02-12       Impact factor: 6.167

Review 8.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

9.  Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.

Authors:  F De Benedetti; M Massa; P Pignatti; S Albani; D Novick; A Martini
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

10.  High-level production of alternatively spliced soluble interleukin-6 receptor in serum of patients with adult T-cell leukaemia/HTLV-I-associated myelopathy.

Authors:  S Horiuchi; W Ampofo; Y Koyanagi; A Yamashita; M Waki; A Matsumoto; M Yamamoto; N Yamamoto
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.